Firm will host enterprise replace name on Sept. 24, 2024, at 8:30 a.m. ET
FT. MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (NASDAQ: NASDAQ:), a number one oncology testing companies firm, in the present day issued the next assertion in response to inquiries:
NeoGenomics has cleared the feasibility stage with a brand new model of its RaDaR ® know-how and has resolved litigation with Natera (NASDAQ:) concerning RaDaR 1.0. The Firm will host a enterprise replace convention name and webcast on Tuesday, Sept. 24, 2024, starting at 8:30 a.m. Japanese Time.
The accelerated progress of the brand new RaDaR know-how supplied the Firm the chance to barter a decision with Natera as to RaDaR 1.0. The settlement, whereas confidential, is just not materials to the Firm’s backside line and doesn’t influence its adjusted EBITDA steering vary or liquidity expectations.
The dwell webcast could also be accessed by visiting the Investor Relations part of our web site at ir.neogenomics.com. The webcast shall be archived and out there for replay shortly after the conclusion of the decision.
To entry the dwell name through phone, dial (877) 545-0523 (home) or (973) 528-0016 (worldwide) at the very least 5 minutes previous to the decision. The participant entry code is 196876.
About NeoGenomics, Inc.
NeoGenomics, Inc. focuses on most cancers genetics testing and knowledge companies, offering one of the vital complete oncology-focused testing menus on this planet for physicians to assist them diagnose and deal with most cancers. The Firm’s Pharma Providers Division serves pharmaceutical shoppers in scientific trials and drug improvement.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA licensed laboratories for full-service pattern processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Analysis Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics additionally has a number of, small, non-processing laboratory places throughout the US for offering evaluation companies. NeoGenomics serves the wants of pathologists, oncologists, educational facilities, hospital techniques, pharmaceutical corporations, built-in service supply networks, and managed care organizations all through the US, and pharmaceutical corporations in Europe and Asia.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240923921828/en/
Investor Contact
Kendra Sweeney
[email protected]
Media Contact
Andrea Sampson
[email protected]
Supply: NeoGenomics, Inc.